LONG-TERM EFFICACY AND SAFETY OF MOMELOTINIB IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA: A TWO-YEAR MULTICENTER REAL LIFE STUDY (SIE 2026) - Oct 6, 2026 - Abstract #SP127; "At baseline, median age was 71 (range 5-85) years, 16 (41%) patients were transfusion-dependent, and 84% of cases were previously exposed to ruxolitinib and 36% to fedratinib. These real-world data confirm long-term effica- cy of momelotinib in improving anemia in MF patients, in- cluding those heavily pretreated. Moreover, momelotinib showed a good safety profile, manageable with dose reduc- tion."
Clinical • Anemia • Myelofibrosis • Myeloproliferative Neoplasm • ACVR1 • JAK1 • JAK2
|
|
M. C. Martorelli1; N. Pugliese2; M. Di Perna3; D. De Novellis1,4; A. Lombardi2; L. De Fazio5; G. Loglisci6; I. Peluso7; M. Molica5; C. Copia7; A. Ricco8; A. Bruzzese9; F. Mendicino9; V. De Fazio10; T. M. Santeramo11; R. Bianco12; G. Monaco13; R. Fontana1; R. Guariglia1; B. Serio1; S. Luponio1; A. M. Della Corte1,4; L. Settembre1; F. Squitieri1; A. Malandrini1; V. Giudice1,4; F. Frigeri13; G. Tarantini11; A. Guarini10; M. Gentile9; P. Musto8; M. Annunziata7; N. Di Renzo6; M. Rossi5; C. Califano3; F. Pane2; C. Selleri1,4
|